Characterising the depression pathway in secondary care: a UK-based epidemiological study of patient characteristics, comorbidities, and treatments
Preprint
Abstract
BACKGROUND Depression is a disabling disorder with variable outcomes. In severe cases treatment is provided by specialist mental health care services, yet there is a lack of real-world evidence demonstrating how depression is managed within these settings, and consequently, a limited understanding of how to improve care for this population. AIMS We examine the characteristics of patients receiving secondary mental healthcare for depressive disorders within a UK National Health Service (NHS) provider, and the treatments they receive. We investigate when patients receive treatments, and what predicts the use of specific treatments, improvement, and duration with services, with the aim of comparing real-world care to that advised by national guidelines. METHODS A retrospective cohort study was conducted using de-identified electronic patient records of patients with depression referred to Cambridgeshire and Peterborough NHS Foundation Trust (serving a population ∼0·86 million), between January 2013 and June 2021. ANOVA models examined predictor variables of improvement and duration of care, while survival analyses explored treatment initiation rates and predictors of which treatments were used. RESULTS 9,083 patients met the study’s inclusion criteria. Almost half of those with depression had additional psychiatric diagnoses, reflecting the complexity of cases in secondary care. Treatment within secondary care was associated with improvements in both depressive and overall symptoms. Patients with a greater degree of psychiatric co-morbidity and those with lower socio-economic status indicators presented with greater overall illness severity at baseline, were more likely to be admitted into hospital, spent longer with services, and improved less than the average. Treatment patterns differed across age groups, sex/gender, socio-economic status, and psychiatric comorbidities. Some nationally recommended further-line treatments appeared to be under-used. CONCLUSIONS Treatment gaps in further-line treatments for depression exist, highlighting key areas for service improvement. Future work should target patients with complex needs and those who are socio-economically deprived.Keywords
This publication has 33 references indexed in Scilit:
- The complexity of treatment-resistant depression: A data-driven approachJournal of Affective Disorders, 2024
- Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide StudyJAMA Psychiatry, 2023
- Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health recordsJournal of Affective Disorders, 2022
- Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomesJournal of Affective Disorders, 2021
- Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristicsJournal of Affective Disorders, 2021
- A network meta‐analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depressionWorld Psychiatry, 2020
- Defining treatment‐resistant depressionDepression and Anxiety, 2019
- Associations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort studyInternational Journal of Geriatric Psychiatry, 2014
- A Caution Regarding Rules of Thumb for Variance Inflation FactorsQuality & Quantity, 2007
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005